MA54567A - Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma - Google Patents

Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma

Info

Publication number
MA54567A
MA54567A MA054567A MA54567A MA54567A MA 54567 A MA54567 A MA 54567A MA 054567 A MA054567 A MA 054567A MA 54567 A MA54567 A MA 54567A MA 54567 A MA54567 A MA 54567A
Authority
MA
Morocco
Prior art keywords
pyridimine
pi3k
pyridine
compounds
gamma inhibitors
Prior art date
Application number
MA054567A
Other languages
English (en)
Inventor
Andrew W Buesking
Andrew P Combs
Nikoo Falahatpisheh
Lixin Shao
Stacey Shepard
Richard B Sparks
Haisheng Wang
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MA54567A publication Critical patent/MA54567A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
MA054567A 2016-01-05 2017-01-04 Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma MA54567A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662274942P 2016-01-05 2016-01-05

Publications (1)

Publication Number Publication Date
MA54567A true MA54567A (fr) 2021-10-27

Family

ID=57868380

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054567A MA54567A (fr) 2016-01-05 2017-01-04 Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma

Country Status (7)

Country Link
US (3) US20170190689A1 (fr)
EP (2) EP3400221B1 (fr)
AR (1) AR107293A1 (fr)
ES (1) ES2833955T3 (fr)
MA (1) MA54567A (fr)
TW (1) TW201734003A (fr)
WO (1) WO2017120194A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
MD3371190T2 (ro) 2015-11-06 2022-09-30 Incyte Corp Compuși heterociclici ca inhibitori PI3K-gamma
EP3400221B1 (fr) 2016-01-05 2020-08-26 Incyte Corporation Pyridines substitués par un pyrazole et un imidazole et leur utilisation en tant qu'inhibiteurs de pi3k-gamma
AR108875A1 (es) 2016-06-24 2018-10-03 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
PE20210169A1 (es) 2017-10-18 2021-01-29 Incyte Corp Derivados de imidazol condensados sustituidos por grupos de hidroxia terciaria como inhibidores de pi3k-y gamma
US20210179600A1 (en) * 2017-11-17 2021-06-17 Hepagene Therapeutics (HK) Limited Oxazole and thiazole derivatives as inhibitors of ask1
WO2019119206A1 (fr) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Inhibiteurs puriques de la phosphatidylinositol 3-kinase delta humaine
PT3762368T (pt) 2018-03-08 2022-05-06 Incyte Corp Compostos de aminopirazina diol como inibidores de pi3k-y
DK3847175T3 (da) 2018-09-05 2024-03-18 Incyte Corp Krystallinske former af en phosphoinositid-3-kinase- (pi3k) inhibitor
CN115677692A (zh) * 2019-04-10 2023-02-03 南京征祥医药有限公司 磷脂酰肌醇3-激酶抑制剂
MX2021013786A (es) * 2019-05-14 2021-12-10 Metabomed Ltd Inhibidores de acss2 y metodos de uso de los mismos.
CN111718310B (zh) * 2019-08-19 2021-06-11 中国药科大学 苯基取代的五元杂环类化合物及其制备方法、用途和药物组合物
WO2021242859A1 (fr) * 2020-05-27 2021-12-02 Duke University Compositions et procédés pour sensibiliser des leucémies myéloïdes aiguës à une chimiothérapie
CA3231777A1 (fr) * 2021-09-14 2023-03-23 Craig W. Lindsley Analogues lies a un heteroaryle utilises en tant que modulateurs allosteriques negatifs de mglu5 et leurs procedes de fabrication et d'utilisation

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4269846A (en) 1979-10-29 1981-05-26 Usv Pharmaceutical Corporation Heterocyclic compounds useful as anti-allergy agents
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CN1152031C (zh) 1998-08-11 2004-06-02 诺瓦提斯公司 具有血管生成抑制活性的异喹啉衍生物
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0011092D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (III)
CA2413330A1 (fr) 2000-06-28 2002-01-03 Smithkline Beecham P.L.C. Procede de broyage par voie humide
AU2002337142B2 (en) 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
BR0213562A (pt) 2001-10-26 2004-08-31 Aventis Pharma Inc Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
CA2462657C (fr) 2001-10-30 2011-04-26 Novartis Ag Derives de staurosporine inhibiteurs de l'activite tyrosine kinase du recepteur flt3
DE10207843A1 (de) 2002-02-15 2003-09-04 Schering Ag Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US8524899B2 (en) 2003-03-04 2013-09-03 California Institute Of Technology Alternative heterocycles for DNA recognition
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
ZA200600424B (en) 2003-08-01 2007-05-30 Genelabs Tech Inc Bicyclic imidazol derivatives against flaviviridae
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
WO2005118580A2 (fr) 2004-05-12 2005-12-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Composes tricycliques utiles comme inhibiteurs du mecanisme de signalisation hypoxique
CN101106983A (zh) 2004-11-24 2008-01-16 诺瓦提斯公司 JAK抑制剂与至少一种Bcr-Abl、Flt-3、FAK或RAF激酶抑制剂的组合
EP1909910A1 (fr) 2005-08-04 2008-04-16 Sirtris Pharmaceuticals, Inc. Dérivés de benzimidazole en tant que modulateur du sirtuin
EP1928237A4 (fr) 2005-09-02 2011-03-09 Abbott Lab Nouveaux heterocycles a base imidazo
HUE032640T2 (en) 2005-11-08 2017-10-30 Vertex Pharma Heterocyclic modulator of ATP-binding cassette transcripts
ES2340093T3 (es) 2006-06-22 2010-05-28 Biovitrum Ab (Publ) Derivados pirazina y piridina como inhibidores de cinasa mnk.
CA2681813A1 (fr) 2007-03-27 2009-01-08 Paratek Pharmaceuticals, Inc. Composes modulant le facteur de transcription et leurs procedes d'utilisation
DE102007035333A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009079011A1 (fr) 2007-12-19 2009-06-25 The Scripps Research Institute Benzimidazoles et analogues comme inhibiteurs de la rho-kinase
EP2240023A4 (fr) 2008-01-15 2010-12-29 Siga Technologies Inc Médicaments antiviraux pour le traitement d'une infection par un arénavirus
AR071523A1 (es) 2008-04-30 2010-06-23 Merck Serono Sa Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento
WO2009158118A2 (fr) 2008-05-30 2009-12-30 University Of Notre Dame Du Lac Agents antibactériens produits à partir d'échafaudages benzo[d]hétérocycliques utilisés pour prévenir et traiter une bactérie multirésistante aux antibiotiques
EP2358202B1 (fr) 2008-11-03 2016-06-15 Merck Sharp & Dohme Corp. Benzimidazole et aza-benzimidazole carboxamides
WO2010061903A1 (fr) * 2008-11-27 2010-06-03 塩野義製薬株式会社 Dérivé de pyrimidine et dérivé de pyridine présentant tous deux une activité inhibitrice de pi3k
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
EP2401273A1 (fr) 2009-02-27 2012-01-04 Vertex Pharmaceuticals Incorporated Inhibiteurs tricycliques de pyrazolopyridine kinase
CN102458581B (zh) 2009-05-22 2016-03-30 因塞特控股公司 作为JANUS激酶抑制剂的吡唑-4-基-吡咯并[2，3-d]嘧啶和吡咯-3-基-吡咯并[2，3-d]嘧啶的N-(杂)芳基-吡咯烷衍生物
ME01838B (me) 2009-06-29 2014-12-20 Lncyte Holdings Corp Pirimidinoni kao inhibitori pi3k
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011075643A1 (fr) 2009-12-18 2011-06-23 Incyte Corporation Dérivés condensés d'hétéroaryles substitués à titre d'inhibiteurs de pi3k
US8680108B2 (en) 2009-12-18 2014-03-25 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
WO2011099832A2 (fr) 2010-02-12 2011-08-18 Crystalgenomics, Inc. Nouveau composé de benzimidazole, son procédé de préparation et composition pharmaceutique le contenant
ME02386B (fr) 2010-03-10 2016-09-20 Incyte Holdings Corp Dérivés de pipéridin-4-yl azétidine en tant qu'inhibiteurs de jak1
US20130018039A1 (en) 2010-03-31 2013-01-17 Bodmer Vera Q Imidazolyl-imidazoles as kinase inhibitors
US9193721B2 (en) 2010-04-14 2015-11-24 Incyte Holdings Corporation Fused derivatives as PI3Kδ inhibitors
WO2011149856A1 (fr) 2010-05-24 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibiteurs de ns5a du vhc
WO2011149874A2 (fr) * 2010-05-26 2011-12-01 Schering Corporation Inhibiteurs n-phénylimidazolecarboxamides de la protéine kinase 3-phosphoinositide-dépendante de type 1
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
JP2013542941A (ja) 2010-10-13 2013-11-28 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヘテロアリールおよびその使用
EP2640723A1 (fr) 2010-11-19 2013-09-25 Incyte Corporation Dérivés pyrrolopyridine et pyrrolopyrimidine à substitution cyclobutyle utilisés comme inhibiteurs des jak
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
EP2649062B1 (fr) 2010-11-30 2015-04-08 Takeda Pharmaceutical Company Limited Composes bicycliques en tant qu`inhibiteurs d'acetyle-coa-carboxylase (acc)
EP2655374B1 (fr) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(phényl substitué)éthyl)-9h-purin-6-amines en tant qu'inhibiteurs de pi3k
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US8673905B2 (en) 2011-03-17 2014-03-18 Hoffmann-La Roche Inc. Imidazo pyrazines
WO2012135009A1 (fr) 2011-03-25 2012-10-04 Incyte Corporation Dérivés de pyrimidine-4,6-diamine en tant qu'inhibiteurs de pi3k
US9029389B2 (en) 2011-04-21 2015-05-12 Institut Pasteur Korea Anti-inflammation compounds
ES2602813T3 (es) 2011-06-09 2017-02-22 Rhizen Pharmaceuticals S.A. Nuevos compuestos como moduladores de GPR-119
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
MX2020004502A (es) 2011-09-02 2022-01-20 Incyte Holdings Corp Heterociclilaminas como inhibidores de fosfoinositida 3-cinasas (pi3k).
US9212169B2 (en) 2012-03-01 2015-12-15 Hyogo College Of Medicine Benzimidazole derivative and use thereof
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
EP2857396B1 (fr) 2012-05-31 2018-11-21 Sumitomo Chemical Co., Ltd Composés hétérocycliques condensés pour la lutte contre les nuisibles
US9309243B2 (en) 2012-07-13 2016-04-12 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of TNF activity
PE20151141A1 (es) 2012-11-01 2015-08-06 Incyte Corp Derivados triciclicos fusionados de tiofeno como inhibidores de jak
TW202214254A (zh) 2013-03-01 2022-04-16 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
WO2014149207A2 (fr) 2013-03-15 2014-09-25 Dow Agrosciences Llc Compositions insecticides à base de benzimidazole et procédés apparentés
WO2014153529A1 (fr) 2013-03-22 2014-09-25 The Scripps Research Institute Benzimidazoles substitués en tant que modulateurs d'un récepteur de nociceptine
US9394254B2 (en) 2013-05-08 2016-07-19 The University of Denver and Regis University Antibiotic and anti-parasitic agents that modulate class II fructose 1,6-bisphosphate aldolase
ME02763B (fr) 2013-05-17 2018-01-20 Incyte Corp Dérivés de bipyrazole servant d'inhibiteurs de jak
EP4219477A1 (fr) 2013-07-17 2023-08-02 Otsuka Pharmaceutical Co., Ltd. Composés cyanotriazole
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20230044320A (ko) 2014-04-08 2023-04-03 인사이트 코포레이션 Ｊａｋ 및 ｐｉ3ｋ 억제제 조합에 의한 ｂ-세포 악성종양의 치료
EP2930048A1 (fr) 2014-04-10 2015-10-14 Johnson Controls Automotive Electronics SAS Dispositif d'affichage tête haute projetant des informations visuelles sur un écran
WO2015191677A1 (fr) 2014-06-11 2015-12-17 Incyte Corporation Dérivés d'hétéroarylaminoalkylphényle bicycliques à titre d'inhibiteurs de pi3k
US9676770B2 (en) * 2014-09-16 2017-06-13 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
MA40933A (fr) * 2014-11-11 2017-09-19 Piqur Therapeutics Ag Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
MD3371190T2 (ro) 2015-11-06 2022-09-30 Incyte Corp Compuși heterociclici ca inhibitori PI3K-gamma
EP3400221B1 (fr) 2016-01-05 2020-08-26 Incyte Corporation Pyridines substitués par un pyrazole et un imidazole et leur utilisation en tant qu'inhibiteurs de pi3k-gamma
AR108875A1 (es) 2016-06-24 2018-10-03 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g

Also Published As

Publication number Publication date
EP3792256A1 (fr) 2021-03-17
US11952367B2 (en) 2024-04-09
US20220227736A1 (en) 2022-07-21
US20170190689A1 (en) 2017-07-06
EP3400221A1 (fr) 2018-11-14
AR107293A1 (es) 2018-04-18
TW201734003A (zh) 2017-10-01
US20190359592A1 (en) 2019-11-28
EP3400221B1 (fr) 2020-08-26
ES2833955T3 (es) 2021-06-16
US11352340B2 (en) 2022-06-07
WO2017120194A1 (fr) 2017-07-13

Similar Documents

Publication Publication Date Title
MA54567A (fr) Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma
MA43862A (fr) Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA49903A (fr) Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
MA55194A (fr) Composés hétérocycliques en tant qu'immunomodulateurs
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA42990A (fr) Composés utiles en tant qu'immunomodulateurs
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA47120A (fr) Dérivés pyridine utilisés en tant qu'immunomodulateurs
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
MA46091A (fr) Composés biaryles utiles en tant qu'immunomodulateurs
MA45377A (fr) Composés hétérocycliques en tant qu'agents antibacteriens
MA49566A (fr) Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA46196A (fr) Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal
MA52063A (fr) Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MA47576A (fr) Composés inhibiteurs d'oga bicyclique
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA42919A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx